StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck daiichi Sankyo (3 DXd ADC Oncology Programs) — Current payables / liabilities to partner ($M) ($M)

Form 10-Q / 10-K Note 3/4 Collaborative Arrangements

QuarterlyAnnual
Latest, Q2 2026
100
Period ended Jun 30, 2026
Change on a year earlier
-88.2%
850 in Q2 2025
History
11 quarters
Since Q4 2023
Sources
10
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedDaiichi Sankyo (3 DXd ADC Oncology Programs) — Current payables / liabilities to partner ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026100-88.2%Form 10-Q (filed 2026-08-07) ↗
Q1 2026Mar 31, 202685-89.4%Form 10-Q (filed 2026-05-04) ↗
Q4 2025Dec 31, 2025113-86.2%Form 10-Q (filed 2026-08-07) ↗
Q3 2025Sep 30, 2025869+7.2%Form 10-Q (filed 2025-11-05) ↗
Q2 2025Jun 30, 2025850+6.1%Form 10-Q (filed 2025-08-05) ↗
Q1 2025Mar 31, 2025803-1.7%Form 10-Q (filed 2025-05-02) ↗
Q4 2024Dec 31, 2024817+2.1%Form 10-K (filed 2026-02-24) ↗
Q3 2024Sep 30, 2024811–Form 10-Q (filed 2024-11-06) ↗
Q2 2024Jun 30, 2024801–Form 10-Q (filed 2024-08-05) ↗
Q1 2024Mar 31, 2024817–Form 10-Q (filed 2024-05-03) ↗
Q4 2023Dec 31, 2023800–Form 10-K (filed 2025-02-25) ↗

Cite this data

StockData. (2026). Merck Daiichi Sankyo (3 DXd ADC Oncology Programs) — Current payables / liabilities to partner ($M) ($M), quarterly Q4 2023–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/collab_daiichisankyo_ap_cur

See every metric in the Merck KPI table. Data updated Oct 26, 2026.